Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes

AAPS PharmSciTech

Volumn 16, Issue 1, 2014, Pages 45-52

  Mooranian, Armin ^a   Negrulj, Rebecca ^a   Al Sallami, Hesham S ^b   Fang, Zhongxiang ^c   Mikov, Momir ^d,e   Golocorbin Kon, Svetlana ^d,e   Fakhoury, Marc ^f   Watts, Gerald F ^g   Matthews, Vance ^h   Arfuso, Frank ^a   Lambros, Amanda ^c   Al Salami, Hani ^a,c  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CURTIN UNIVERSITY   (Australia)

^d UNIVERSITY OF NOVI SAD   (Serbia)

^e UNIVERSITY OF MONTENEGRO   (Montenegro)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

anti inflammatory; antioxidant; artificial cell microencapsulation; diabetes mellitus; probucol; type 2 diabetes

Indexed keywords

ALGINIC ACID; PROBUCOL; DELAYED RELEASE FORMULATION; HYPOCHOLESTEROLEMIC AGENT; MICROCAPSULE;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; GASTROINTESTINAL TRACT; IN VITRO STUDY; MICROCAPSULE; MICROENCAPSULATION; MICROSCOPY; MOISTURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SURFACE CHARGE; SURFACE PROPERTY; TEMPERATURE; WATER TRANSPORT; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; BODY FLUID; CHEMISTRY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DIFFUSION; HUMAN; ORAL DRUG ADMINISTRATION; PROCEDURES; SYNTHESIS;

ADMINISTRATION, ORAL; ANTICHOLESTEREMIC AGENTS; BODY FLUIDS; CAPSULES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DIFFUSION; DRUG COMPOUNDING; DRUG STABILITY; HUMANS; HYDROGEN-ION CONCENTRATION; PROBUCOL; TEMPERATURE;

EID: 84922014441     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0205-9     Document Type: Article

References (43)

1. Barbeau WE, Bassaganya-Riera J, Hontecillas R. Putting the pieces of the puzzle together—a series of hypotheses on the etiology and pathogenesis of type 1 diabetes. Med Hypotheses. 2007;68(3):607–19.
2. Moore PA, Zgibor JC, Dasanayake AP. Diabetes: a growing epidemic of all ages. J Am Dent Assoc. 2003;134(Spec No):11S–5S.
3. Negrulj R, Mooranian A, Al-Salami H. Potentials and limitations of bile acids in type 2 diabetes: applications of microencapsulation as a novel oral delivery system. J Endocrinol Diabetes Mellitus. 2013;1:1–11.
4. Cani PD et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50(11):2374–83.
5. Goldfine AB, Fonseca V, Shoelson SE. Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem. 2011;57(2):162–7.
6. Wu R et al. Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets. Dig Dis Sci. 2013;58(1):163–71.
7. Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis. 2009;207(1):16–23.
8. Shimizu H et al. Probucol attenuated hyperglycemia in multiple low-dose streptozotocin-induced diabetic mice. Life Sci. 1991;49(18):1331–8.
9. Russell JC et al. Cardioprotective effect of probucol in the atherosclerosis-prone JCR:LA-cp rat. Eur J Pharmacol. 1998;350(2–3):203–10.
10. Zimetbaum P, Eder H, Frishman W. Probucol: pharmacology and clinical application. J Clin Pharmacol. 1990;30(1):3–9.
11. Vedantham K et al. Development of a probucol-releasing antithrombogenic drug eluting stent. J Biomed Mater Res B Appl Biomater. 2012;100(4):1068–77.
12. Nourooz-Zadeh J et al. Measurement of plasma probucol levels by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1994;654(1):55–60.
13. Ajun W et al. Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohydr Polym. 2009;75(4):566–74.
14. Mooranian A, Negrulj R, Martinez J, Mathavan S, Sciarretta J, Chen-Tan N, et al. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov, 2014 (in press).
15. Mooranian A, Negrulj R, Martinez J, Mathavan S, Sciarretta J, Chen-Tan N, Mukkur TK, Mikov M, Lalic-Popovic M, Stojančević M, Golocorbin-Kon S, Al-Salami H, A complex microencapsulated system: a platform for optimised oral delivery of antidiabetic drug-bile acid formulations. Pharmaceutical Development and Technology, 2014 (in press).
16. Pal D, Nayak AK. Novel tamarind seed polysaccharide-alginate mucoadhesive microspheres for oral gliclazide delivery: in vitro-in vivo evaluation. Drug Deliv. 2012;19(3):123–31.
17. Awasthi R, Kulkarni GT. Development of novel gastroretentive drug delivery system of gliclazide: hollow beads. Drug Dev Ind Pharm, 2013(0):1–11.
18. Mooranian A, et al. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov, 2014:1–8.
19. Mooranian A, et al. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterisation study. Drug Des Dev Ther, 2014 (in press).
20. Mladenovska K et al. 5-ASA loaded chitosan–Ca–alginate microparticles: preparation and physicochemical characterization. Int J Pharm. 2007;345(1):59–69.
21. Abdelbary A, El-Gendy NA, Hosny A. Microencapsulation approach for orally extended delivery of glipizide: in vitro and in vivo evaluation. Indian J Pharm Sci. 2012;74(4):319–30.
22. Duro R et al. The adsorption of cellulose ethers in aqueous suspensions of pyrantel pamoate: effects on zeta potential and stability. Eur J Pharm Biopharm. 1998;45(2):181–8.
23. Xie HG et al. Effect of surface wettability and charge on protein adsorption onto implantable alginate chitosan alginate microcapsule surfaces. J Biomed Mater Res Part A. 2010;92(4):1357–65.
24. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan—a review. J Control Release. 2006;114(1):1–14.
25. Yang L et al. Physicochemical and biological characterization of monoketocholic acid, a novel permeability enhancer. Mol Pharm. 2009;6(2):448–56.
26. Mikov M et al. Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur J Drug Metab Pharmacokinet. 2006;31(3):237–51.
27. Mikov M et al. Pharmacokinetics and hypoglycaemic effect of 3 alpha, 7 alpha-dihydroxy-12-oxo-5beta-cholanate (MKC) in diabetic rat. FEBS J. 2006;273:210.
28. Al-Salami H et al. Probiotic treatment proceeded by a single dose of bile acid and gliclazide exert the most hypoglycemic effect in type 1 diabetic rats. Med Hypothesis Res. 2008;4(2):93–101.
29. Mikov M et al. The influence of 3alpha, 7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 2008;33(3):137–42.
30. Al-Salami H et al. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep. 2008;60(4):532–41.
31. Al-Salami H et al. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2012;37(2):99–108.
32. Al-Salami H et al. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2009;34(1):43–50.
33. Al-Salami H et al. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet. 2008;33(2):101–6.
34. Al-Kassas RS, Al-Gohary OM, Al-Faadhel MM. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharm. 2007;341(1–2):230–7.
35. Efentakis M, Buckton G. The effect of erosion and swelling on the dissolution of theophylline from low and high viscosity sodium alginate matrices. Pharm Dev Technol. 2002;7(1):69–77.
36. Silva CM et al. Insulin encapsulation in reinforced alginate microspheres prepared by internal gelation. Eur J Pharm Sci. 2006;29(2):148–59.
37. Andersen E, Karlaganis G, Sjovall J. Altered bile acid profiles in duodenal bile and urine in diabetic subjects. Eur J Clin Investig. 1988;18(2):166–72.
38. Cook MT et al. Microencapsulation of probiotics for gastrointestinal delivery. J Control Release. 2012;162(1):56–67.
39. Duboc H et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531–9.
40. Caesar R, Fak F, Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med. 2010;268(4):320–8.
41. Cani PD et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–103.
42. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001;73(2):121–36.
43. Narasimhan B, Langer R. Zero-order release of micro-and macromolecules from polymeric devices: the role of the burst effect. J Control Release. 1997;47(1):13–20.